Sort   by:  
 Page size 
UnknownA randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.
Not available
S-EPMC4647871 | biostudies-literature
UnknownGenetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study
Not available
S-EPMC12345293 | biostudies-literature
UnknownEfficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
Not available
S-EPMC8084805 | biostudies-literature
UnknownSafety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial.
Not available
S-EPMC8669119 | biostudies-literature
UnknownEffect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
Not available
S-EPMC9720565 | biostudies-literature
UnknownDifferent association of gBRCA1 and gBRCA2 variants with HER2-low status in invasive breast cancer: findings from a Ukrainian study.
Not available
S-EPMC12774882 | biostudies-literature
UnknownImpact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Not available
S-EPMC5913649 | biostudies-literature
UnknownUpdated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial.
Not available
S-EPMC11875137 | biostudies-literature
UnknownRandomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
Not available
S-EPMC6469669 | biostudies-literature
UnknownCardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.
Not available
S-EPMC10080377 | biostudies-literature
Sort   by:  
 Page size